key: cord-0771769-q90o7w9y
authors: Fendler, Annika; Au, Lewis; Shepherd, Scott T.C.; Byrne, Fiona; Cerrone, Maddalena; Boos, Laura Amanda; Rzeniewicz, Karolina; Gordon, William; Shum, Ben; Gerard, Camille L.; Ward, Barry; Xie, Wenyi; Schmitt, Andreas M.; Joharatnam-Hogan, Nalinie; Cornish, Georgina H.; Pule, Martin; Mekkaoui, Leila; Ng, Kevin W.; Carlyle, Eleanor; Edmonds, Kim; Del Rosario, Lyra; Sarker, Sarah; Lingard, Karla; Mangwende, Mary; Holt, Lucy; Ahmod, Hamid; Stone, Richard; Gomes, Camila; Flynn, Helen R.; Agua-Doce, Ana; Hobson, Philip; Caidan, Simon; Howell, Michael; Wu, Mary; Goldstone, Robert; Crawford, Margaret; Cubitt, Laura; Patel, Harshil; Gavrielides, Mike; Nye, Emma; Snijders, Ambrosius P; MacRae, James I; Nicod, Jerome; Gronthoud, Firza; Shea, Robyn L.; Messiou, Christina; Cunningham, David; Chau, Ian; Starling, Naureen; Turner, Nicholas; Welsh, Liam; van As, Nicholas; Jones, Robin L.; Droney, Joanne; Banerjee, Susana; Tatham, Kate C.; Jhanji, Shaman; O’Brien, Mary; Curtis, Olivia; Harrington, Kevin; Bhide, Shreerang; Bazin, Jessica; Robinson, Anna; Stephenson, Clemency; Slattery, Tim; Khan, Yasir; Tippu, Zayd; Leslie, Isla; Gennatas, Spyridon; Okines, Alicia; Reid, Alison; Young, Kate; Furness, Andrew J.S.; Pickering, Lisa; Gandhi, Sonia; Gamblin, Steve; Swanton, Charles; Nicholson, Emma; Kumar, Sacheen; Yousaf, Nadia; Wilkinson, Katalin A.; Swerdlow, Anthony; Harvey, Ruth; Kassiotis, George; Larkin, James; Wilkinson, Robert J.; Turajlic, Samra
title: Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study
date: 2021-09-20
journal: Res Sq
DOI: 10.21203/rs.3.rs-916427/v1
sha: dcd6806b9c72904c012056ed69925d0cacf36e86
doc_id: 771769
cord_uid: q90o7w9y

Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study (NCT03226886) integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2-positive, 94 were symptomatic and 2 patients died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies, 82% had neutralizing antibodies against WT, whereas neutralizing antibody titers (NAbT) against the Alpha, Beta, and Delta variants were substantially reduced. Whereas S1-reactive antibody levels decreased in 13% of patients, NAbT remained stable up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment-specific, but presented compensatory cellular responses, further supported by clinical. Overall, these findings advance the understanding of the nature and duration of immune response to SARS-CoV-2 in patients with cancer.

Patients with cancer have an increased risk of severe outcomes from coronavirus disease 2019 123 , 1,2 with risk factors including general (e.g. increased age, male sex, obesity, co-124 morbidities) as well as cancer-specific features (e.g. haematological and thoracic malignancies, 125 active cancer, poor performance status). [3] [4] [5] [6] [7] [8] The precise effects of anti-cancer treatments on the 126 course and outcome of SARS-CoV-2 infection are yet to be fully understood, with different reports 127 yielding conflicting results. 5, 7, 9, 10 Understanding of the immune response to SARS-CoV-2 in this 128 heterogeneous population, spanning multiple malignancy types and numerous treatment regimens, 129 is crucial for optimal clinical management of those patients during the ongoing pandemic. 149 were male, 89% had solid malignancy, and the majority (64%) had advanced disease ( Table 1) .

Overall, 118 patients (33%; 97 with solid cancers and 21 with haematological malignancies), were 151 classified as SARS-CoV-2-positive according to our case definition (positive SARS-CoV-2 RT-PCR 152 and/or ELISA for S1-reactive antibodies, at/or prior to study enrolment), and were included in the 153 analysis (Figure 1a ,b, see Methods). The most common comorbidities were hypertension (27%), 154 obesity (21%) and diabetes mellitus (11%); no significant baseline differences were observed 155 between patients with solid and haematological malignancies ( 

Overall, 88% patients received SACT (51% chemotherapy; 21% targeted therapy; 12% immune 157 checkpoint inhibitors [CPI] ; 5% anti-CD20), 10% had radiotherapy and 13% underwent surgery in the 158 12 weeks prior to infection. Response to the most recent anti-cancer intervention is shown in Table   159 2. 182 Thirty-three patients (28%) were hospitalised due to COVID-19, with a median duration of 183 in-patient stay of nine days (range: 1-120); 27 (23%) required supplemental oxygen, seven (6%) were 184 admitted to an intensive care unit (ICU), with one (1%) requiring mechanical ventilation and 185 inotropic support (Table 3) . Thirteen patients (11%) were treated with corticosteroids (>10 mg 186 prednisolone equivalent), and three patients (3%) received tocilizumab. Nine patients (8%) had a 187 thrombo-embolic complication. At database lock, eleven SARS-CoV-2-positive patients (9%) died of 188 progressive cancer, and two patients (2%) died due to recognised complications of COVID-19 (Table   189 3). patients had S1-reactive antibodies, and among the symptomatic patients there was a non-significant trend for higher S1-reactive antibody titres in those with higher COVID-19 severity (P = 214 0.057) (Figure 2a ).

Thirteen patients (11%), with median follow up of 49 days (range: 14-344), had no evidence 216 of S1-reactive antibodies but were positive by SARS-CoV-2 RT-PCR. Six further patients without 217 detectable S1 antibody had no follow-up. Lack of seroconversion was significantly associated with 218 haematological malignancies: 9/21 patients (43%) with haematological vs 10/97 patients (10%) with 219 solid malignancies did not seroconvert (p = 0.0012). Antibody titres were also significantly lower in 220 patients with haematological malignancies (Figure 2b ). Two patients with long COVID did not 221 seroconvert at any point during follow up.

A sensitive flow cytometric assay conducted on sera from a subset of patients with S1- Finally, we evaluated matched pre-pandemic sera from 47 patients, 10 with and 37 without 229 S1-reactive antibodies in their sample collected during the pandemic. We found no evidence of S1-230 reactive antibodies in the pre-pandemic sera in any patient (Extended Data Figure 2g ), but S-231 reactive IgG or IgM were detected in 18 patients without S1-reactive antibodies indicating cross-232 reactivity to seasonal human coronaviruses. (Figure 2d) . In a binary logistic regression model including all cancer 242 patients (n=118), presence of haematological malignancy, but not comorbidities, age, sex, or COVID-243 19 severity was associated with lack of NAb (Figure 2e ). In patients with solid tumours (n=97), there 244 was no association with cancer type, stage, progressive disease or cancer therapy (Figure 2f,g) 

There was a significant correlation between S1-reactive and NAbT for all variants (P < 0.01) 255 (Extended Data Figure 2h) ; but we note that presence of S1-reactive antibodies was not always 256 predictive of neutralising response, especially to VOCs. 257 258 SARS-CoV-2 antibody response lasts up to 11 months 259 Next, we assessed antibody kinetics in 81/97 patients with S1-reactive antibodies and known 260 timing of POD (n=70 solid tumours, n=11 haematological malignancy). We analysed a median of two 261 timepoints per patient (range: 1-10) at a median follow-up of 56 days after POD (range: 1-344). 

SsT-cell compensation in patients without humoral response 296 Patients with haematological malignancies had a wide range of antibodies (Figure 4a,b) and SsT-cell 297 responses. In patients with leukaemia, NAb were detected in 6/11 and SsT-cells in 5/10 evaluable 298 patients (two had both CD4+ and CD8+, two had CD4+ only, and one had CD8+ only). In patients 299 with myeloma, 2/4 had NAb, and 3/4 had detectable SsT-cells (two both CD4+ and CD8+, one CD4+ 300 only). None of the six lymphoma patients, including five who were treated with anti-CD20, had 301 detectable NAbs, while SsT-cells were detected in 5/6 (three had both CD4+ and CD8+, one had 302 CD4+ only, and one had CD8+ only). One further patient with AML treated with anti-CD20 had 303 neither NAb nor SsT-cell responses. In total, we observed a discordance between antibody and T-cell 304 responses amongst patients with haematological malignancy, whereby 7/9 patients with NAbT to 305 WT SARS-CoV-2 lacked SsT-cell response (CD4+ and/or CD8+), and in 12 patients without NAb 306 activity 7 had SsT-cell response. (Figure 4c 

Whole blood was collected in EDTA tubes (VWR) and stored at 4ºC until processing. All samples were 557 processed within 24 hours. Time of blood draw, processing, and freezing was recorded for each 558 sample. Prior to processing tubes were brought to room temperature (RT). PBMC and plasma were 559 isolated by density-gradient centrifugation using pre-filled centrifugation tubes (pluriSelect). Up to 560 30 ml of undiluted blood was added on top of the sponge and centrifuged for 30 minutes at 1000g at 561 RT. Plasma was carefully removed then centrifuged for 10 minutes at 4000g to remove debris, 

There are restrictions to the availability based on limited quantities. Response to any request for 711 data and/or materials will be given within a 28 day period. Data and materials that can be shared 712 would then be released upon completion of a material transfer agreement. 

and the Wellcome Trust (FC10988); the National Institute for Health Research

Biomedical Research Centre at the Royal Marsden Hospital and Institute of Cancer Research (grant 748 reference number A109), the Royal Marsden Cancer Charity, The Rosetrees Trust (grant reference 749 number A2204), Ventana Medical Systems Inc (grant reference numbers 10467 and 10530), the 750 National Institute of Health

is Royal Society Napier Research Professor (RP150154)

which receives its core funding from Cancer Research UK (FC001169)

Medical Research Council (FC001169), and the Wellcome Trust (FC001169). C.S. is funded by Cancer 754 Research UK (TRACERx, PEACE and CRUK Cancer Immunotherapy Catalyst Network)

Research UK Lung Cancer Centre of Excellence, the Rosetrees Trust

NovoNordisk Foundation (ID16584)

Award (RP/EA/180007), the NIHR BRC at University College London Hospitals, the CRUK-UCL Centre

His 759 research is supported by a Stand Up To Cancer-LUNGevity-American Lung Association Lung Cancer 760

Stand Up To Cancer 761 is a program of the Entertainment Industry Foundation

American Association for Cancer Research, the Scientific Partner of SU2C. C.S. also receives funding 763 from the European Research Council (ERC) under the European Union's Seventh Framework 764

European Commission ITN 765 (FP7-PloidyNet 607722), an ERC Advanced Grant (PROTEUS) from the European Research Council 766 under the European Union's Horizon 2020 research and innovation programme

Chromavision from the European Union's Horizon 2020 research and innovation programme 768 (665233). R.W. has received Francis Crick Institute supported by Wellcome (FC0010218)

Rosetrees (M926) and The South African MRC

Novartis and Ipsen. ST has the following 782 patents filed: Indel mutations as a therapeutic target and predictive biomarker PCTGB2018/051892 783 and PCTGB2018/051893 and Clear Cell Renal Cell Carcinoma Biomarkers P113326GB. N.Y. has 784 received conference support from Celegene

has received research funding from Bristol-Myers Squibb, Merck, Novartis

Secarna, and Vitaccess. I.C. has served as a 790 consultant to Eli-Lilly

acknowledges receipt of research funding from Pfizer 794 and Roche; speakers fees from Pfizer, Seagen, Lilly and AstraZeneca

Archer Dx Inc (collaboration in minimal 798 residual disease sequencing technologies) and Ono Pharmaceutical, is an AstraZeneca Advisory 799 Board member and Chief Investigator for the MeRmaiD1 clinical trial

European patents 804 relating to assay technology to detect tumour recurrence (PCT/GB2017/053289); to targeting 805 neoantigens (PCT/EP2016/059401), identifying patent response to immune checkpoint blockade 806 (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of 807 patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment 808 (PCT/GB2018/051912), a US patent relating to detecting tumour mutations (PCT/US2017/28013) 809 and both a European and US patent related to identifying insertion/deletion mutation targets 810

has recieved institutional research 812 funding from Astrazeneca, Tesaro, GSK; speakers fees from Amgen

Mersana and has an advisor role for Amgen

has received 815 speaker's fee from Merck Sharp & Dohme

Factors associated with COVID-19-related death using OpenSAFELY. 953

Mortality in patients with cancer and coronavirus disease 2019: A 955 systematic review and pooled analysis of 52 studies

Impact of hematologic malignancy and type of cancer therapy on

COVID-19 severity and mortality: lessons from a large population-based registry study

COVID-19 in patients with thoracic malignancies (TERAVOLT): first 961 results of an international, registry-based, cohort study

COVID-19 mortality in patients with cancer on chemotherapy or other 964 anticancer treatments: a prospective cohort study

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort 967 study

Association of clinical factors and recent anticancer therapy with COVID-19 969 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

COVID-19 prevalence and mortality in patients with cancer and the effect 972 of primary tumour subtype and patient demographics: a prospective cohort study

COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes 975 from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study

Determinants of COVID-19 disease severity in patients with cancer

CD8(+) T cells contribute to survival in patients with COVID-19 and 980 hematologic cancer

Acute Immune Signatures and Their Legacies in Severe Acute 982

Respiratory Syndrome Coronavirus-2 Infected Cancer Patients

Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant 985 disease and association with anticancer therapy

Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study

A minimal common outcome measure set for COVID-19 clinical research

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort 992 study

Association of Smoking and Cumulative 994

Pack-Year Exposure With COVID-19 Outcomes in the Cleveland Clinic COVID-19 Registry

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with 999 COVID-19 Disease and Unexposed Individuals

Immunological memory to SARS-CoV-2 assessed for up to 8 months after 1001 infection

Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-1003 19 and associations with age and disease severity

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 1005 patients with acute respiratory distress syndrome

Helper Cell Biology: A Decade of Discovery and Diseases

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed 1010 humans

Seroconversion in patients with cancer and oncology health care workers 1012 infected by SARS-CoV-2

Evidence for antibody as a protective correlate for COVID-19 vaccines

Neutralizing antibody levels are highly predictive of immune protection 1016 from symptomatic SARS-CoV-2 infection

Longitudinal observation and decline of neutralizing antibody responses in the 1019 three months following SARS-CoV-2 infection in humans

Evolution of antibody immunity to SARS-CoV-2

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after 1024 infection

SARS-CoV-2 antibody dynamics and B-cell memory response over time in

COVID-19 convalescent subjects

SARS-CoV-2 variants of concern exhibit reduced sensitivity to live-virus 1028 neutralization in sera from CoronaVac vaccinees and naturally infected COVID-19 patients. medRxiv

Humoral and circulating follicular helper T cell responses in recovered 1031 patients with COVID-19

Interferon-gamma release assay for accurate detection of SARS-CoV-2 T 1033 cell response

The PD-1 Pathway Regulates Development and Function of Memory 1035

CD8<sup>+</sup> T Cells following Respiratory Viral Infection

PD-1 signalling in CD4(+) T cells restrains their clonal expansion to an 1038 immunogenic stimulus, but is not critically required for peptide-induced tolerance

Altered cellular and humoral immune responses following SARS-CoV-1041 2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. medRxiv

T cell responses are required for protection from clinical 1044 disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice

Early induction of functional SARS-CoV-2-specific T cells associates with rapid 1047 viral clearance and mild disease in COVID-19 patients

Animal models for COVID-19

COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell 1052 responses

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 1054 (AZD1222) vaccine in a phase 1/2 clinical trial

Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity 1057 in infected or vaccinated individuals

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or 1060

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and 1062 uninfected controls

Defining the true impact of coronavirus disease 2019 in the at-risk 1064 population of patients with cancer

Scalable and robust SARS-CoV-2 testing in an academic center

Nextflow enables reproducible computational workflows

CoronaHiT: high-throughput sequencing of SARS-CoV-2 genomes

The nf-core framework for community-curated bioinformatics pipelines

Reduced antibody cross-reactivity following infection with B.1.1.7 than 1078 with parental SARS-CoV-2 strains. bioRxiv

inpatients: every 2 -14 days; outpatients: every clinical visit maximum every 3-6 weeks in year one and every six months in year two, and at the start of every or every-second cycle of treatment). Clinical data, oronasopharyngeal swabs and blood were collected at each study visit. Viral antigen testing (RT-PCR on swabs), antibody (ELISA, ow cytometric assay), T cell response and IFN-γ activation assays were performed. b) Distribution of SARS-CoV-2 infection, and S1-reactive Ab status and COVID-19 severity in patients with cancer

SARS-CoV-2 infection status by RT-PCR and S1-reactive Ab were analysed at recruitment and in serial samples. RT-PCR results prior to recruitment were extracted from electronic patient records

case de nition includes all patients with either RT-PCR con rmed SARS-CoV-2 infection or S1-reactive Ab

Solid bars indicate time to the last positive test, dotted lines denote the time from the last positive test to the rst negative test. d) Distribution of symptoms in 118 COVID-19 patients. Bar graph denotes the number of patients. Each row in the lower graph denotes one patient. ONP, Oronasopharyngeal; ELISA, enzyme-linked immunoassay; PBMCs, peripheral blood mononuclear cells; WGS -whole genome sequencing

Signi cance was tested by Kruskal-Wallis test, p = 0.074. b) S1-reactive AbT by cancer type (Solid patients: n= 92, Haematological patients: n=20)

Signi cance was tested by two-sided Wilcoxon-Mann-Whitney U test, p = 0.052. Boxes indicate 25 and 75 percentiles, line indicates median, and whiskers indicate 1.5 times the IQR. Dots represent individual samples

Wald z-statistic was used two calculate two-sided p-values. *, p = 0.038. f) Multivariate binary logistic regression evaluating the association of lack of NAb in patients with solid cancer

Dot denotes odds ratio (blue, positive odds ratio; red, negative odds ratio); whiskers indicate 1.5 times the IQR. h) NAbT against WT, Alpha, Beta, and Delta VOCs in patients (n=112) infected with WT SARS-CoV-2 or Alpha VOC. Violin plots denote density of data points. PointRange denotes median and 25 and 75 percentiles. Dots represent individual samples. Signi cance was tested by Kruskal Wallis test, p = 3.5e-07, two-sided Wilcoxon Mann Whitney U-test with Bonferroni correction (post-hoc test) was used for pairwise comparisons

Blue line denotes loess regression line with 95% con dence bands in grey. Black dots denote patients with one sample, coloured dots denote patients with serial samples (n=51 patients). Samples from individual patients are connected. Dotted lines and grey areas at bottom indicate limit of detection. NAb, neutralising antibody, NAbT

Frequency of Sars-CoV-2-speci c e) CD4+ and f) CD8+ T cells in haematological patients with cancer (n= 21). Stimulation index was calculated by dividing the percentage of positive cells in the stimulated sample by the percentage of positive cells in the negative control (NC)

myeloma (n=4), and lymphoma (n=6). b) Neutralising antibody titres in patients with leukaemia (n=10), myeloma (n=4), and lymphoma (n=6). c) CD4+ and CD8+ cells T cells across patients with leukemia (n=10), myeloma (n=4), or lymphoma (n=6)

Signi cance was tested by two-sided Wilcoxon-Mann-Whitney U test

Signi cance was tested by two-sided Wilcoxon-Mann-Whitney U test, p < 0.05 was considered signi cant. g) CD4+ and CD8+ cells T cells across patients with solid cancer (n=81) by cancer subtype. Boxes indicate the 25 and 75 percentiles, line indicates the median, and whiskers indicate 1.5 times the IQR. Dots represent individual patient samples. Dotted lines and grey boxes denote the limit of detection

Associations between SARS-CoV-2-speci c T cells with patient or cancer-speci c features Multivariate binary logistic regression analysis evaluating associations between SARS-CoV-2-speci c a) CD4+ and b)

comorbidities, age, sex, and COVID-19 disease severity in 100 patients. Wald z-statistic was used two calculate two-sided p-values. *, p = 0.038. Multivariate binary logistic regression analysis evaluating associations between SARS-CoV-2-speci c c) CD4+ and d) CD8+ T cells with anti-cancer intervention, age, sex, and COVID-19 disease severity in patients with solid cancer (n=81)

Dot denotes odds ratio (blue and red dots indicate positive or negative odds ratio, respectively) ; whiskers indicate 1.5 times the IQR. e) Comparison of SARS-CoV-2-speci c CD4+/CD8+ T cells between patients with solid malignancies on CPI (n=13, administered within three months) and not on CPI (n=68). Boxes indicate the 25th and 75th percentiles, line indicates the median, and whiskers indicate 1.5 times the IQR. Dots represent individual samples